1. Pulmonary response in sarcoidosis
Pulmonary response in sarcoidosis. a) Change in pulmonary function after 26 weeks of infliximab therapy in patients with a pulmonary treatment indication (change in % predicted); b) mean forced vital capacity (FVC) 6 months before initiation and during 26 w...
Pulmonary response in sarcoidosis. a) Change in pulmonary function after 26 weeks of infliximab therapy in patients with a pulmonary treatment indication (change in % predicted); b) mean forced vital capacity (FVC) 6 months before initiation and during 26 weeks of infliximab therapy in the total cohort (% pred). Bars represent sem. FEV1: forced expiratory volume in 1 s; DLCOc: diffusing capacity of the lung for carbon monoxide corrected for haemoglobin.
Adriane D.M. Vorselaars et al. Eur Respir J 2015;46:
©2015 by European Respiratory Society